Combining chemotherapy with immunotherapy before surgery for resectable head and neck squamous cell carcinoma achieves significantly greater tumor reduction than immunotherapy alone. According to a study published Aug. 13 in JAMA Otolaryngology-Head & Neck Surgery, patient response rates reach 67 percent under the combination protocol.
Pathologic Response Rates in Real-World Patients
Researchers evaluated 86 real-world patients diagnosed with resectable head and neck squamous cell carcinoma to compare outcomes between neoadjuvant immunotherapy alone and neoadjuvant chemoimmunotherapy. The evaluation measured both pathologic complete response and major pathologic response, defined as having 10 percent or less viable tumor remaining at the time of surgical resection.
Across the entire cohort, investigators documented that 29 percent of participants achieved a pathologic complete response. An additional 17 percent attained a major pathologic response.
Chemoimmunotherapy Versus Immunotherapy Alone
Patients who received the combined chemoimmunotherapy regimen experienced a dramatic advantage in tumor destruction compared to those treated with immunotherapy alone. For recipients of neoadjuvant chemoimmunotherapy, pathologic complete response or major pathologic response occurred in 67 percent of cases. By contrast, only 3.6 percent of patients who received neoadjuvant immunotherapy alone reached those same response thresholds.
A propensity score-adjusted analysis reinforced these disparities, indicating that the multi-agent approach was associated with substantially higher odds of achieving a major or complete pathologic response, with an odds ratio of 29.1.
Tolerability and Surgical Timelines
Clinical evaluation of the preoperative combination regimen showed that the aggressive multi-agent protocol maintained an acceptable safety profile for surgical candidates. The treatment was generally well tolerated, resulting in few adverse event-related delays to surgery.
This manageable toxicity profile is notable given the complex supportive care challenges inherent in head and neck oncology. Acute and late toxicities—such as mucositis, xerostomia, dysphagia, malnutrition, sarcopenia, pain, ototoxicity, nephrotoxicity, endocrine dysfunction, and immune-related adverse events—frequently threaten treatment delivery and functional independence, as frontiersin.org research highlights across broader supportive care pathways.
Expert Perspectives on Personalized Treatment
Investigators from the Icahn School of Medicine at Mount Sinai in New York City emphasized that while the findings mark an important advancement, additional clinical validation is necessary before altering standard care paradigms.
“We found that giving a combination of chemotherapy with immunotherapy before surgery led to much greater destruction of the tumor than immunotherapy alone.”
Scott Roof, M.D., Icahn School of Medicine at Mount Sinai
Ethan A. Gomez and colleagues noted that financial ties to the biopharmaceutical industry were disclosed by one study author. Researchers stressed that the work remains ongoing.
“Our work is far from complete, and additional testing in larger sample sizes is required, but these findings are an important first step in providing a more personalized approach to head and neck cancer treatment.”
Scott Roof, M.D., Icahn School of Medicine at Mount Sinai
